STANFORD, October 10 — Stanford Medicine administered the world’s first commercial dose of Orca-T on October 7, 2026, marking the therapy’s debut outside clinical trials after its FDA approval in June 2026. By the numbers, 78% of patients treated with Orca-T in the pivotal phase 3 trial were free from moderate-to-severe graft-versus-host disease one year post-transplant, compared to 38.4% receiving standard hematopoietic grafts. That figure formed the core evidence for regulatory clearance.
The trial also showed improved survival without increasing relapse risk. Orca-T is a Treg cell-based immunotherapy engineered specifically to reduce GVHD, a common and serious complication where donor immune cells attack the recipient’s body.
Unlike conventional transplants that infuse a mixed graft of stem cells, immune cells, and early blood cells in a single dose, Orca-T delivers precisely defined cell types at staggered time points. The treatment was developed by Stanford scientists led by Robert Negrin, MD, former chief of the Stanford Medicine Blood and Marrow Transplantation & Cellular Therapy Division. His research on regulatory T cells spans more than two decades, predating the therapy’s approval by over 20 years.
David Miklos, MD, PhD, who now leads that division, noted that Orca-T decreases transplantation toxicity, especially GVHD, and expressed optimism that future iterations could integrate targeted anti-cancer immune cells to further reduce relapse risk. Stanford Cancer Institute, where the research was conducted, holds designation as a National Cancer Institute-designated comprehensive cancer center and is affiliated with Stanford Medicine.
The October 7 administration represented the first time Orca-T was given as an approved commercial product, transitioning from investigational use to real-world application. Investors will note that no financial figures — including drug pricing, development costs, or market valuation — were disclosed in connection with Orca-T’s launch. Looking ahead, clinicians and researchers will watch for broader adoption of Orca-T in transplant centers, real-world outcomes data beyond the trial setting, and whether the platform’s engineering principles can be adapted to target cancer relapse directly.
The success of this first commercial dose may influence how cell therapies are sequenced and dosed in future hematopoietic transplant protocols.
Sources
More Personal Finance coverage: Mortgage Rates Today, Monday, October 5: A Little Lower
